World’s First! Predicting the effectiveness of Immune Checkpoint Inhibitor. Expected to establish a personalized medical therapy for liver cancer -- Kindai University
- Predicted effectiveness of immune checkpoint inhibitors (ICIs) using a scoring system related to anti-cancer immune conditions
Developed a highly sensitive measurement system for diagnosis of high-risk prostate cancer. Enabling highly effective and rapid detection of cancer while reducing the burden on patients -- Kindai University
- Measures serum core-type fucosylated PSA, which was not possible in the past, with high speed and high sensitivity - Verified that fucosylated PSA index significantly rises in a man with high-risk prostate cancer - Adjunct in the conventional PSA test, high-risk prostate cancer can be effectively detected
Efficacy of Opdivo (Nivolumab) in Cancer of Unknown Primary Cases Confirmed - Kindai University
- Efficacy of molecular target drug Nivolumab verified in investigator-initiated clinical trial for use with CUP by hospital team from Kindai University’s Faculty of Medicine - Reductions by more than half in tumor size in over 20% of CUP patients observed - Nivolumab expected to become standard treatment for CUP cases with no standard treatment
Preclinical Stage Verification for Combined Use of a Drug Under Development with an Existing Drug to Stimulate the Immune System to Attack Cancer Cells - Kindai University
The research team from Kindai University's Faculty of Medicine, in cooperation with DAIICHI SANKYO COMPANY, LIMITED, have verified at the preclinical stage that using the currently under-development anti-cancer drug, U3-1402*1, in combination with immune checkpoint inhibitors*2 has the potential to be an effective treatment.
Ground Breaking Development of World’s First CurativeTreatment of Intractable Hepatocellular Carcinoma Path to Establishment of Standard Treatment of Hepatocellular Carcinoma - Kindai University
Senior Administrator Masatoshi Kudo of Kindai University Faculty of Medicine, Department of Gastroenterology and Hepatology, with his research group has invented a new method (LEN-TACE) of treating patients with intractable multinodular or large liver cancers, particularly those with near advanced liver cancer.